A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
PHASE1CompletedINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
Not specified
Study Completion Date
February 28, 1990
Conditions
HIV Infections
Interventions
DRUG
Ampligen
Trial Locations (2)
20037
George Washington Univ Med Ctr, Washington D.C.
170330850
Milton S Hershey Med Ctr, Hershey
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000735 - A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC | Biotech Hunter | Biotech Hunter